Sirolimus in the Treatment of Vascular Anomalies

Abstract

Aim of the Study mTOR inhibitors are showing promising results in the management of vascular anomalies. Although current controlled trials remain to be completed, many individual experiences are being published. We present our series of children with complex vascular anomalies treated with sirolimus.

Patients and Methods A retrospective review of 41 patients treated with sirolimus between January 2011 and December 2015 was performed: 15% (n = 6) had vascular tumors (4 kaposiform hemangioendotheliomas, 1 PTEN) and 85% (n = 35) had malformations (13 generalized lymphatic anomalies/Gorham–Stout diseases [GSD], 1 kaposiform lymphangiomatosis [KLA], 11 large lymphatic malformations (LMs) in critical areas, 2 lymphedemas, 4 venous malformations, and 4 aggressive arteriovenous malformations [AVM]). Several variables were collected: type of vascular anomaly, duration of treatment, dosage, response, and secondary effects.

Results There was a female predominance (1.4:1). All patients received sirolimus, at initial dosage of 0.8 mg/m²/12 hour. Overall successful response rate was 80.4% of cases, presenting improvement in radiologic imaging and reduction of symptoms, at a median time of 10 weeks. Patients showing no response included four AVMs, one GSD, one LM, one KLA, and one unknown tumor. Sirolimus was well tolerated, even in neonates, with insignificant side effects. No patients had complete resolution and no patients worsened on therapy. Thirty patients remain under treatment at the present moment.

Conclusion Sirolimus has become a new therapeutic option for patients with vascular anomalies that do not respond to other treatments. Unfortunately, important questions as what is the most appropriate dosage and for how long should the patient be treated remain unanswered. An international registry followed by customized controlled trials is mandatory to clarify the future of this therapy.

Keywords

vascular anomalies - sirolimus - mTOR inhibitors - pediatrics

• References

• 1 Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69 (3) 412-422
• 2 The International Society for the Study of Vascular Anomalies . Available at: www.issva.org/ . Accessed September 13, 2016
• 3 Wassef M, Blei F, Adams D , et al; ISSVA Board and Scientific Committee. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics 2015; 136 (1) e203-e214
• 4 Dasgupta R, Fishman SJ. Vascular anomalies in infants and children. Preface. Semin Pediatr Surg 2014; 23 (4) 157-238
• 5 Hammill AM, Wentzel M, Gupta A , et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57 (6) 1018-1024
• 6 Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82 (4) 381-388
• 7 Yang G, Yang L, Yang X , et al. Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis. Exp Ther Med 2015; 9 (2) 626-630
• 8 Nadal M, Giraudeau B, Tavernier E, Jonville-Bera AP, Lorette G, Maruani A. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol 2016; 96 (4) 448-452
• 9 Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010; 14 (3) 402-408
• 10 Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol 2013; 30 (6) e194-e197
• 11 Huang L, Mulliken J, Bischoff J. Rapamycin (Sirolimus) Inhibits Proliferation and Increases Vascular Maturation of GLUT1-positive Endothelial Cells from Infantile Hemangioma. Abstract ISSVA; 2016
• 12 Oza VS, Mamlouk MD, Hess CP, Mathes EF, Frieden IJ. Role of sirolimus in advanced kaposiform hemangioendothelioma. Pediatr Dermatol 2016; 33 (2) e88-e92
• 13 Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55 (7) 1396-1398
• 14 Alemi AS, Rosbe KW, Chan DK, Meyer AK. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations. Int J Pediatr Otorhinolaryngol 2015; 79 (12) 2466-2469
• 15 Cramer SL, Wei S, Merrow AC, Pressey JG. Gorham-Stout disease successfully treated with sirolimus and zoledronic acid therapy. J Pediatr Hematol Oncol 2016; 38 (3) e129-e132
• 16 Powell J , et al. Extensive arteriovenous malformation of the brain and mandible associated with nevus sebaceous syndrome (Schimmelpenning syndrome). 2016: Abstract ISSVA
• 17 Grunewald TG, Damke L, Maschan M , et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol 2010; 21 (8) 1733-1734
• 18 Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med 2012; 366 (4) 384-386